Page 43 - 77_04

M.C.
AVENDAÑO

27.
Fenton,
J.
W.,
&
Shen,
G.
X.
(1999).
Statins
as
cellular
antithrombotics.
Haemostasis,
29,
166-­-
169.

28.
Jialal,
I.,
Stein,
D.,
Balis,
D.,
Adams-­-Huet,
B.,
&
Devaraj,
S.
(2001).
Effect
of
hydroxymethyl

glutaryl
coenzyme
A
reductase
inhibitor
therapy
on
high
sensitive
C-­-Reactive
protein
levels.

Circulation,
103,
1933-­-1935.

29.
Kwak,
B.,
Mulhaupt,
F.,
&
Mach,
F.
(2000).
Statins
as
a
newly
recognized
type
of

immunomodulator.
Natural
Medicine,
6,
1399-­-1402.

30.
Laufs,
U.,
La
Fata,
V.,
Plutzky,
J.,
&
Liao,
J.
K.
(1998).
Upregulation
of
endotelial
nitric
oxide

synthase
by
HMG-­-CoA
reductase
inhibitors.
Circulation,
97,1129-­-1135.

31.
Hindler,
K.,
Cleeland
,
C.
S.,
Rivera,
E.,
&
Collard,
C.
D.
(2006).

The
role
of
statins
in
cancer

therapy.
The
Oncologist,
11,
306-­-315.

32.
Sassano,
A.,
&
Platanias,
L.
C.
(2008).
Statins
in
tumor
suppression.
Cancer
Letters,
260,
11-­-19.

33.
Fritz,
G.
(2009).
Targeting
the
mevalonate
pathway
for
improved
anticancer
therapy.
Current

Cancer
Drug
Targets,
9,
626-­-638.

34.
Rouhi,
M.
(2005).
Top
Pharmaceuticals:
Thalidomide,
Chemical
&
Engineering
News,
83,122-­-
123.

35.
Blaschke,
G.,
Kraft,
H.
P.,
Fickentscher,
K.,
&
Kohler,
F.
(1979).
Chromatographic
separation
of

racemic
thalidomide
and
teratogenic
activity
of
its
enantiomers
(traducción).

Arzneimittelforschung,
29,
1640–1642.

36.
Eriksson,
T.,
Bjorkman,
S.,
&
Hoglund,
P.
(2001).
Clinical
pharmacology
of
thalidomide.
Eur.
J.

Clin.
Pharmacol.
57,
365–376.

37.
Sampaio.
E.
P.,
Sarno,
E.
N.,
Galilly,
R.,
Cohn,
Z.
A.,
&
Kaplan,
G.
(1991).
Thalidomide
selectively

inhibits
tumor
necrosis
factor
(a)
production
by
stimulated
human
monocytes.
J.
Exp.
Med.,

173,
699-­-703.

38.
Corral,
L.
G.,
&
Kaplan,
G.
(1999).
Immunomodulation
by
thalidomide
and
thali-­-
domide

analogues.
Annals
of
the
Rheumatic
Diseases,
58,
1107-­-1113.

39.
González
Infante,
E.
(2001).
Desarrollo
químico
y
galénico
de
la
talidomida
como
medicamento

huérfano,
Tesis
Doctoral
UCM,
ISBN:
84-­-669-­-2012-­-9.

40.
Dimopoulus,
M.,
Spencer,
A.,
Attal,
M.,
Prince,
H.
M.,
Harousseau,
J.
L.,
Olesnyckyj,
M.,
Yu,
Z-­-,

Patin,
J.,
Zeldis,
J.
B.,
&
Knight,
R.
D.
(2007).
Lenalidomide
plus
dexamethasone
for
relapsed
or

refractory
múltiple
myeloma.
N.
Engl.
J.
Med.,
357,
2123-­-32.

41.
Schmahl,
H.
J.,
Nau,
H.,
&
Neubert,
D.
(1988).
The
enantiomers
of
the
teratogenic
thalidomide

analogue
EM
12:
Chiral
inversion
and
plasma
pharmacokinetics
in
the
marmoset
monkey.

Archives
of
Toxicology,
62,
200–204.

42.
Teo,
S.
K.,
Chen,
Y.,
Muller,
G.
W.,
Chen,
R.
S.,
Thomas,
S.
D.,
Stirling,
D.
I.,
&
Chandula,
R.
S.

(2003).
Chiral
inversion
of
the
second
generation
of
CC-­-4047
in
human
plasma
and
phosphate-­-
buffered
saline.
Chirality,
15,
348–351.

43.
Yamada,
T.,
Okada,
T.,
Sakaguchi,
K.,
Ohfune,
Y.,
Ueki,
H.,
&
Soloshonok,
V.
A.
(2006).
Efficient

asymmetric
syntheses
of
novel
4-­-substituted
and
configurationally
stable
analogues
of

thalidomide.
Organic
Letters,
8,
5625–5628.

44.
Krejsa,
C.
M.,
Horvath,
D.,
Rogalski,
S.
L.,
Penzotti,
J.
E-­-,
Mao,
B.,
Barbosa,
&
F.,
Migeon,
J.
C.

(2003).
Predicting
ADME
properties
and
side
effects:
the
BioPrint
approach,
Current
Opinion
in

Drug
Discovery,
6,
470–480.

45.
Bender,
A.,
Scheiber,
J.,
Glick,
M.,
Davies,
J.
W.,
Azzaoui,
K.,
Hamon,
J.,
Urban,
L.,
Whitebread,
S.,

&
Jenkins,
J.
L.
(2007).
Analysis
of
pharmacology
data
and
the
prediction
of
adverse
drug

reactions
and
off-­-target
effects
from
chemical
structure.
Chem.
Med.
Chem.,
6,
861-­-873.

46.
Chua,
H.
N.,
&
Roth,
F.
P.
(2011).
Discovering
the
Targets
of
Drugs
Via
Computacional
Systems

Biology.
J.
Biol.
Chem.,
286,
23653-­-23658.

74